Literature DB >> 12412998

Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.

Toshihiro Hamada1, Ichiro Hisatome, Yoshiharu Kinugasa, Koichi Matsubara, Hideki Shimizu, Hiroaki Tanaka, Masako Furuse, Kazuhiko Sonoyama, Yasutaka Yamamoto, Akira Ohtahara, Osamu Igawa, Chiaki Shigemasa, Tetsuya Yamamoto.   

Abstract

OBJECTIVE: The acute effects of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism were evaluated.
METHODS: Losartan (50 mg) was administered orally to 6 healthy males. Blood and urine samples for uric acid and oxypurine were collected before and up to 6 hours after losartan administration. The same examinations were performed later using enalapril (5 mg).
RESULTS: Losartan decreased the serum uric acid concentration (from 5.9 +/- 0.9 to 5.2 +/- 1.0 mg/dl) and increased its fractional clearance, which reached a maximum after 2 hours, while enalapril did not. Losartan also induced an increase in the plasma concentration of hypoxanthine, peaking in the fourth hour, and a decrease in its urinary clearance, while the plasma xanthine concentration and its urinary clearance were unchanged. The extent of uric acid excretion was much greater than that of the oxypurines.
CONCLUSIONS: Losartan, which has a high affinity for the urate/anion exchanger, has a transient uricosuric effect. Our data indicate that losartan induces a significant decrease in the urinary excretion of hypoxanthine without changes in xanthine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12412998     DOI: 10.2169/internalmedicine.41.793

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

Review 1.  Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care.

Authors:  Hyon K Choi; Natalie McCormick; Chio Yokose
Journal:  Nat Rev Rheumatol       Date:  2021-12-17       Impact factor: 32.286

2.  Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.

Authors:  Atsushi Hosomi; Takeo Nakanishi; Takuya Fujita; Ikumi Tamai
Journal:  PLoS One       Date:  2012-02-10       Impact factor: 3.240

3.  Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.

Authors:  Hyon K Choi; Lucia Cea Soriano; Yuqing Zhang; Luis A García Rodríguez
Journal:  BMJ       Date:  2012-01-12

4.  Genetics of kidney disease and related cardiometabolic phenotypes in Zuni Indians: the Zuni Kidney Project.

Authors:  Sandra L Laston; V Saroja Voruganti; Karin Haack; Vallabh O Shah; Arlene Bobelu; Jeanette Bobelu; Donica Ghahate; Antonia M Harford; Susan S Paine; Francesca Tentori; Shelley A Cole; Jean W MacCluer; Anthony G Comuzzie; Philip G Zager
Journal:  Front Genet       Date:  2015-01-30       Impact factor: 4.599

5.  Losartan and Eprosartan Induce a Similar Effect on the Acute Rise in Serum Uric Acid Concentration after an Oral Fructose Load in Patients with Metabolic Syndrome.

Authors:  Anna Masajtis-Zagajewska; Jacek Majer; Michał Nowicki
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021-08-25       Impact factor: 1.636

6.  Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria.

Authors:  Charlotte E Bryant; Azita Rajai; Nicholas J A Webb; Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2021-04-21       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.